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SUMMARY.-The distribution of 3H-chlorambucilfollowing its administration
by subcutaneous injection to Yoshida ascites tumour-bearing rats has been
examined, in an attempt to elucidate the metabolic fate and mode of action of
this drug.
Drug uptake into the body tissue was rapid, with a high level ofradioactivity
being associated with the plasma and ascitic fluid during the initial 6-hour
period after treatment. Previous studies in vitrohad shownthat chlorambucil
-
resistant cells accumulated less drug than their sensitive counterparts: this
discrepancy was also observed after in vivo drug treatment and was reflected
in the two-fold difference in extent of binding of tritium to DNA, RNA and
protein isolated from the2 cell strains. These results might in partexplain the
observed difference in metabolism ofchlorambucilbythe resistant and sensitive
strain of Yoshida ascites sarcoma cells.
CHLORAM13UCIL has been used extensively for the treatment of chronic
lymphoblastic leukaemia (Boesen et al., 1964), but the development of resistance
to the drug has restricted its usefulness. An understanding of the factors
responsible, particularly its mode ofaction, transport and tissue distributionmight
lead to a widerapplication ofthisdrug in cancerchemotherapy. At present there
is no detailed information concerning these factors, in eitherexperimental animals
or men.
-An in vivo study of the tissue and cellular distribution ofisotopically-labelled
chlorambucil (586mCi/mmole) in ratsbearing a chlorambucil-sensitive or chloram-
bucil-resistant Yoshida ascites sarcoma has therefore been made in an attempt to
elucidate the metabolicfate and mode ofaction ofthisdrug.
MATERIALS AND METHODS
Full details of tumour transplantation techniques have been described pre-
viously (Harrap and Hill, 1969). Tritium-labelled chlorambuc'll 4-(4-di-(2-
chloroethyl)amino-3,5_3H phenyl)butyric acid was synthesized by the reductive
tritiation of the iodinated derivative in the Chester Beatty Research Institute
(Jarman, unpublished work, 1970). The drug was administered subcutaneously
to animalsbearingthe Yoshida ascites sarcomainasciticform at adoseof8 mg./kg.
body weight on the. fourth day following tumour transplantation because this
dose induced complete regression of the sensitive tumour but was without effect
on the growth rate ofthe resistant tumour (Harrap.and Hill, 1969).832 B. T. HILL AND P. G. RICHES
Reagent chemicals were obtained from Hopkin and Williams Ltd. or British
Drug Houses Ltd., AnalaR grades being used where available.
Metabolic 3tudie,3
At intervals after drug administration, animals were anaesthetized with ether,
and bloodsamples removedby cardiac punctureusingheparin as theanticoagulant
(1.0 i.u./ml.). Plasma samples were obtained by centrifugation of whole blood
at 350 g for 15 minutes at 4' C. The animals were killed and ascitic fluid collected
and separated from tumour cells by centrifugation. The tumour cells remaining
in the peritoneum were aspirated with ice-cold 0-3% saline, washed in a solution
of phosphate-buffered saline (PBS)* and resuspended to a known volume. The
cell concentration was determiiied using a modified Fuchs-Rosenthal counting
chamber. Tissue samples were removed from kidney, heart, liver, spleen, lung
and gastrocnemius muscle, and their wet weights determined by difference using
pre-weighed sample tubes.
The excretory rates of tritium-labelled material under these experimental
conditions were determined by collecting urine and faeces separately at various
time intervals from rats confined in glass metabolism cages (Jencons).
Radioactive counting
Plasma and ascitic fluid were diluted 3-fold, and whole blood 30-fold, and
solubilized in 12-5% aqueous tetraethylammonium hydroxide (TEH). Solid
tissues (approximately 50 mg. wet weight) were oxidized to completion using a
Packard TriCarb sample Oxidizer. Aliquots of cell suspensions containing
approximately 5 X 107 cells were centrifuged at 500 g (4') and washed twice with
5 ml. volumes of ice-cold PBS. The resultant cell pellets were then either
(a) Dissolved in 12-5% aqueous TEH (for measurement of gross drug uptake
by the cells), or
(b) Extracted by shaking for I minute successively with 2 x 2 ml. volumes
of ethanol (4'), allowed to stand at O' for 30 minutes before removing and keeping
the ethanol supernatant fraction, or
(c) Subjected to a modification of the Schmidt-Thannhauser technique to
obtain DNA, RNA and protein containing fractions (Munro and Fleck, 1966).
Aliquots of these extracts were assayed for radioactivity using a Toluene-
Phosphor scintillant in a Packard TriCarb Liquid Scintillation Counter Model
3375.
DNA was estimatedaccording to Burton (1956), RNA by the orcinolprocedure
(Brown, 1946) andproteinby the method ofLowry, Rosebrough, Farr and Randall
(1951).
Each calculated figure represents the mean value of duplicate experimental
samples from 3 animals.
RESULTS
Following subcutaneous injection of 3H-chlorambucil, drug uptake into the
body tissues wasrapid. After 1, hour's exposure to thedrug, ofthe tissuesstudied,
the higheSt 3H-concentration was found in the liver. The tissue concentrations
The following abbrev'at'ons will be tised throughout this paper: PBS-phosphate buffered
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of labelled material expressed as a fraction of the corresponding liver value
(86 x 103 DPM/mg. wet weight of tissue) are shown in Table 1. It should be
noted that after this initial interval (I hour after treatment) the concentration of
tritium increased in kidney, but the levels in the other tissues decreased with
respect to time, the tritium being cleared most rapidly from the liver.
In whole blood the radioactive label was mainly associated with the plasma:
the tritium concentration in blood and ascitic fluid was similar. A high level of
radioactivity was associated with these fluids throughout the first 6-hour period
following treatment (Table 11).
In none of these measurements were there significaiit differences in the extent
of drug binding to tissues or fluids in animals bearing either the druff-sensitive zn
TABLE I.-Di-stribution of Radioactivity in Yo-shida Ascite8 Tumour Bearing Rats
fter a Single, Subcutaneous Injection of 8 mg.1kg. 3H-Chlorambucil Expressed
a-s a Fraction of the (Initial) Liver Value-s at I hour in DPMI-,ng. wet weight
Time after drug administration (hours)
Oi-gan 1 6 48
Liver* 1.00 0-48 0-17
Lung 0-22 0-14 WW
Kidney 0-63 0-88 ( 1r)I
Heart, 0.11 (.10 O (7
muscle 0-07 (.06 0-04
Spleen 0-06 0-07 (.06
Resistant ascites tumour cells 0-04 0-05 0-07
Liver contained 86-2 x 103 DPM/mg. wet weight I hour after drug treatment. Assuming all
the tritium were associated with chlorambuell, this value would be equivalent, to 7 x 10-9 mmole's,
chlorambucil per mg. wet weight of tissue.
TABLE H.-Distribution qf Radioactivity in Pla-sma and A86tic Fluid from Rats
Bearing the Yoshida A-scites SarcomaFollowing aSingle Subcutaneous Injection of 3H-Chlorambucil
Time after drug administration (hours) DPM/ml. fltild
X 106 1 6 12 24 48
Ascitic fluict 6-6 8-1 2-6 1.9 1-8
Plasma 4-3 6.7 2-5 2-2 2-1
or -resistant tumours. However, differences were apparent when the total cellular
uptake of the drug and its binding to nucleic acids and protein in the tumour cells
was determined. The concentration of tritium in the sensitive and resistant cells
was similar during the first hour after drug administration (Fig. 1). The level
in the resistant cells increased slightly (20%) to a maximum value approximately 6 hours after treatment, whilst the level associated with the sensitive cells doubled
during this time interval. After this period the 3H-concentration in both cell
strains decreased, but the sensitive cells still maintained 2-3 times more tritium
than the resistant cells.
It has been shown that free chlorambucil (i.e. notprotein or nucleic acidbound)
can be extracted from tumour cells by treatment with ethanol (Hill, Jarman and
Harrap, I'971); 80% of the total tritium counts associated with the cells were
extractable by this procedure I hour after subcutaneous drug injection. This834 B. T. HILL AND P. G. RICHES
percentage decreased with time (Table III). But even at the period of maximum
uptake of labeRed material by the cells (6 hours after treatment) 50% of the
counts could be extracted into ethanol.
Peak binding of3H-chlorambucil to proteins and nucleic acids of ascites cells
occurred at discrete time intervals in the 2 tumour strains, namely 6 and 12 hour-S
after treatment in the drug-resistant and drug-sensitive ceRs respectively. This
peakbinding oftritium to sensitive cells occurred later than theperiod ofmaximal
drug uptake by whole cells. Both cell strains had similar quantities of tritium
associated with their nucleic acids and proteins during the first hour after drug
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FIG. I.-Radioactivity associated with the ascites tumour cellsfollowing asingle subcutaneous
injection of 3H-chlorambucil (8mg./kg.) to tumour-bearing rats. *..e sensitive cells,
O..o resistant cells. Each point represents the mean from 3 separate animals-overall
scatter at each point, IO
injection, but after th'is period the sensitive cells were shown to contain approxi-
mately 2-3 times more bound drug than the resistant cells. In sensitive and
TABLIF, III.-The Percentagm of the Total Tritium Count8 A88ociated with the
Y08hida A8Cite8 Tumour CeIM which were Extractable into Ethanol, after a
SingleSubcutaneou8Injectionof3H-Chlorambucil intoTumour-bearing Anima18
% of total "H-counts per cell
extractable into ethanol
Time after
A
injection Sensitive Resistant
(hours) tumour cells tumour cells
1.0 82 84
6-0 47 52
12-0 28 27
24-0 16 183H-CHLORAMBUCIL IN YOSHIDA SARCOMA RATS 835
resistant cells the RNA appeared to be more extensively labened than the DNA
and protein (Fig. 2).
The 3H activity recovered in the urine following a single doseof 3H-chloram-
bucil amounted to 33% of the total administered dose when the urine had been
collected for a period of 6 hours and to about 60% after 24 hours. Negligible
C_.' 4z;l
quantities ofthe tritium in urine were shown to be associated with tritiated water,
since a similar recovery of tritium was obtained after
(i) direct measurement oftritium in urine, and
(ii) re-estimation of its tritium content after reducing urine to dryness under
vacuum and reconstituting with water.
Tritium associated with the faecal pellets over the 24 hour period was less than
0-2% of the total administered dose. No differences in excretory pattems of
3H-labelled materials were observed between animals bearing the 2 tumour
strains of tumour.
OPM/mg. DNA DPM/mg. RNA OPM/mg. PROTEIN
,)_ jA4 2x 10-
104
25 50 25 so 25 50
TIME AFTER INJECTION (HOURS)
FiG. 2.-Distribution ofradioactivity between DNA, RNA and protein (isolated by a modified
Schmidt-Thannhauser procedure) from drug-sensitive and -resistant Yoshida ascites cells
following a single subcutaneous injection of 3H-chlorambucil (8 mg./kg.) to tumour-bearing rats. *..* sensitive cells, 0..Oresistant cells. Each point represents the mean
from 3 separate animals-overall scatter at each point, IO
DISCUSSION
The data presented above are concerned only with measurements of tritium
concentrations in the body tissues and no attempt has been made in these experi-
ments to identify any of the chlorambucil metabolites with which the tritium
label may be associated. A detailed study of these metabolites is at present under investigation in these laboratories.
The results of the study described here indicate a relatively uniform distribu-
tion of tritium after the administration of 3H-chlorambucil to tumour-bearing
rats, in accord with the data ofMilner, Klatt, Young and Stehlin (I965), who failed
to detect any significant localization ofisotopes in specific tissues in studies with
2-chloroethyl derivatives. In these experiments tritium concentrated primarily in liver and kidney. This was anticipated since a function of these organs is to
protect the host from any adverse effects of foreign substances. Accumulation
of label in most organs was maximal within I hour except in kidney where the
concentration of tritium increased during the initial 24-hour period of study.836 B. T. HILL AND P. G. RICHES
The progressive rapid loss of label from the liver after initial uptake, was similar
to datapresentedby Connors and Melzack (I971) using CB 1954 and Ball, Connors,
Double, Ujhazy and Whisson (1966) using Melphalan. While approximately
60% of the administered radioactivity had been excreted in the urine 24 hours
after treatment, of the remaining 40%, approximately 33% could be accounted
for in terms of the tritium associated with the body tissues: there was negligible
excretion via the faeces. Measurements of exhaled tritium were not made,
neither was an estimate ofthe tritium concentration in the brain or cerebro-spinal
fluid obtained.
More drug entered the sensitive tumour cells than the resistant cells, which
confirms previous data obtained using in vitro systems (Harrap and Hill, 1970;
Hill, Jarman and Harrap, 1971). However, after the in vivo treatment described
above, the initial uptake of the drug by the cells was similar (i.e. I hour after
treatment). Only after this period of time was the difference between the 2 cell
strains apparent. These results might be explained by reference to the different
metabolism of the drug by these cells in vitro, namely that the resistant cells have
a greater ability to hydrolyse and metabolize the drug (Harrap and Hill, 1970).
Maximal uptake of labelled compound by the cells did not occur until 6 hours
after treatment: this was also the time of peak concentration of label in plasma
and ascitic fluid. During this initial period the greater proportion of 3H-labelled
material associated with the cells was shown to be extractable into ethanol:
this was in agreement with previous in vitro studies in which a
" lipophylic-
association
" of chlorambucil was demonstrated (Hill, Jarman and Harrap, 1971).
Furthermore, it is only after, or coincident with this period that peak binding to
cell macromolecules in both cell strains is noted, which wouldsupport thehypothe-
sis that there can be slow release from this lipophylic association followed by
subsequent binding to protein and nucleic acids. These data would suggest that
chlorambucil may exert a cytotoxic effect by intracellular binding over a much
longer period than might be assumed from its short chemical half-life and rapid
rate of hydrolysis (Ross, 1962), especially in the drug-sensitive ascites cell.
These findings may also be related to the clinical observation that chemotherapy
with chlorambucilonlyproduces a maximal effect several months after its adminis-
tration to the patient (Boesen and Davis, 1969). Attempts are now being made
to isolate the metabolites produced and to characterize more fully the identity of
the compound which possesses theselipophylic properties (i.e. whether under these
conditions it retains an active mustard group). The fact that peak cellular
binding oftritium in sensitive cells occurredonly 12 hours aftertreatment, which is
much later than with Melphalan (Ball et al., 1966), may also serve to emphasize
individual differences between alkylating agents and could be related to the much
delayed effects that chlorambucil, in contrast toMelphalan, has on thegrowth rates
of the chlorambucil-sensitive Yoshida ascites cells (Harrap and Hill, 1969):
in drug-sensitive tumour-bearing animals, no effect on thegrowth is observed until
24 hours after treatment.
Whilst peak macromolecular binding in the sensitive cells occurred only
6 hours after maximum drug uptake, this delay was not apparent in the resistant
cells, with peak binding occurring 6 hours after treatment; this effect may be
associated with differing metabolism of the drug, and more details of the identity
of the binding species must be obtained in order to determine the significance of
these findings.3H-CHLORAMBUCIL IN YOSHIDA SARCOMA RATS 837
Work with 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (Oliverio, Vietzke,
Williams and Adamson, 1970) has demonstrated that it is the cyclohexyl portion
ofthe molecule and not the chloroethvl seLyment which is bound to protein. Since
the active mustard group of chlorambucil cannot be detected in the plasma or
urine 6 hours after treatment, this may mean that the binding after treatment
which occurs at thisperiod, andsubsequently in the cells, may also involve another
part of the chlorambucil molecule other than the 2-chloroethyl groups.
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